Rydex Biotechnology Inv
(RYOIX)
US Markets Closed
AdChoices
80.00
+1.07
+1.35%
:

Previous Close

78.93

Net Assets

293.85M

Yield

0.00%

Front load

None

Expenses

1.36%

Category

Health

Morningstar Risk

High

Morningstar Rating ★★★
AdChoices
Performance
Returns %
Key statistics
  • Composition
  • Performance
  • Top Holdings
  • Top Rated Funds
  • Fund vs. Category
Quarterly Returns
  • Annual

  • RYOIX

  • Category

    • 2013

    • 54.66%

    • -

    • 2012

    • 36.54%

    • -

    • 2011

    • 11.39%

    • -

    • 2010

    • 10.56%

    • -

    • 2013

    • 2012

    • 2011

      • Q1

      • 18.29%

      • 21.70%

      • 7.13%

      • Q2

      • 5.43%

      • 6.48%

      • 9.40%

      • Q3

      • 20.40%

      • 9.24%

      • -13.98%

      • Q4

      • 3.01%

      • -3.54%

      • 10.50%

      Composition
      Sector Weightings
      Equity Investment Style
      The two dimensions of the Fund Style box measure the average size of companies that have been in the FUND, from the top to bottom, and the average valuation characteristics of the FUND's past stock holdings, from left to right.
      • Name

      • % Portfolio Weight

      • Shares Held

      • Change

        • Gilead Sciences Inc

        • 7.77

        • 311,392

        • -61,400

        • Amgen Inc

        • 6.18

        • 187,854

        • -30,100

        • Biogen Idec Inc

        • 5.34

        • 68,901

        • -5,800

        • Celgene Corp

        • 5.32

        • 239,521

        • -30,600

        • Regeneron Pharmaceuticals Inc

        • 3.60

        • 42,614

        • -5,700

        • Alexion Pharmaceuticals Inc

        • 3.53

        • 90,776

        • -2,400

        • Vertex Pharmaceuticals Inc

        • 3.38

        • 128,612

        • -24,500

        • Illumina Inc

        • 2.71

        • 70,523

        • -3,273

        • Biomarin Pharmaceutical Inc

        • 2.02

        • 119,774

        • -11,500

        • Incyte Corp Ltd

        • 1.76

        • 153,269

        • 1,700

        • Name

        • Rating

        • YTD Return %

          • T. Rowe Price Health Sciences

          • ★★★★★
          • 21.16

          • VALIC Company I Health Sciences

          • ★★★★★
          • 20.84

          • Prudential Jennison Health Sciences A LW

          • ★★★★★
          • 20.49

          • Prudential Jennison Health Sciences Z

          • ★★★★★
          • 20.79

          • Fidelity® Select Biotechnology Portfolio

          • ★★★★
          • 22.94

          • Vanguard Health Care Inv

          • ★★★★
          • 20.30

          • Fidelity® Select Health Care Portfolio

          • ★★★★
          • 23.00

          • Franklin Biotechnology Discovery A LW

          • ★★★★
          • 23.01

          • Fidelity Advisor® Biotechnology A LW

          • ★★★★
          • 22.93

          • Fidelity Advisor® Health Care A LW

          • ★★★★
          • 22.60

          • Name

          • RYOIX

          • Category

            • Expense Ratio

            • 1.36%

            • 1.45%

            • Net Assets

            • 293.85M

            • 711.24M

            • Dividend Yield

            • 0.22%

            • 0.61

            • Price/Book

            • 5.43

            • 4.82

            • Price/Sales

            • 7.54

            • 3.25

            • Price/Cash Flow

            • 11.03

            • 19.29

            Profile

            Name of Issuer

            Rydex Funds

            Fund Style

            Open

            Fund Manager

            Michael Dellapa

            Investment Style

            Medium Growth

            The investment seeks to provide capital appreciation. Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It will invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.

            Purchase Information

            Initial Purchase 2,500
            Initial Purchase: IRA 1,000
            Initial Purchase: AIP NA
            Front load None
            Back Load None

            Inception

            4/1/1998